Get started
Author

Shifra Ash

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
2020 · Ruth Ladenstein, Ulrike Pötschger, et al. · Cancers · 154
PDF
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study
2020 · Keith Holmes, Ulrike Pötschger, et al. · Journal of Clinical Oncology · 129
PDF
Telomere length is a prognostic factor in neuroblastoma
2006 · Anat Ohali, Smadar Avigad, et al. · Cancer · 89
PDF
The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors
2004 · Smadar Avigad, Ian J. Cohen, et al. · Cancer · 84
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
2021 · Angela Bellini, Ulrike Pötschger, et al. · Journal of Clinical Oncology · 79
PDF
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
2021 · Alberto Garaventa, Ulrike Poetschger, et al. · Journal of Clinical Oncology · 76
Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study
2018 · Daniel A. Morgenstern, Ulrike Pötschger, et al. · Pediatric Blood & Cancer · 74
Apoptosis as a mechanism of T‐regulatory cell homeostasis and suppression
2008 · Esma S Yolcu, Shifra Ash, et al. · Immunology and Cell Biology · 65
A distinct subtype of M4/M5 acute myeloblastic leukemia (AML) associated with t(8:16)(p11:p13), in a patient with the variant t(8:19)(p11:q13)—Case report and review of the literature
1995 · Batia Stark, Peretz Resnitzky, et al. · Leukemia Research · 54
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
2018 · Ana P. Berbegall, Dominik Bogen, et al. · British Journal of Cancer · 47
PDF
Central Nervous System Involvement in Children with Sarcoma
2003 · S. Postovsky, S. Ash, et al. · Oncology · 46
Optimizing the process of fertility preservation in pediatric female cancer patients – a multidisciplinary program
2016 · Irit Ben-Aharon, R. Abir, et al. · BMC Cancer · 45
PDF
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project
2020 · Lucas Moreno, Dongjing Guo, et al. · Pediatric Blood & Cancer · 41
miR-192 Directly Binds and Regulates Dicer1 Expression in Neuroblastoma
2013 · Galina Feinberg-Gorenshtein, Avital Guedj, et al. · PLoS ONE · 41
PDF
2p24 Gain Region Harboring MYCN Gene Compared with MYCN Amplified and Nonamplified Neuroblastoma
2010 · Marta Jeison, Shifra Ash, et al. · American Journal Of Pathology · 40
PDF
Current management of lipoblastoma
2017 · Emmanuelle Séguier-Lipszyc, Artur Baazov, et al. · European Journal of Pediatrics · 38
The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth
2015 · Michal Hameiri-Grossman, Adi Porat-Klein, et al. · Oncotarget · 35
PDF
Short Telomeres: A Novel Potential Predictor of Relapse in Ewing Sarcoma
2007 · Smadar Avigad, Inna Naumov, et al. · Clinical Cancer Research · 35
PDF
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
2018 · Fjoralba Zeka, Anneleen Decock, et al. · JCI Insight · 34
PDF
Metastatic brain involvement in Ewing family of tumors in children
1998 · A. Shuper, I. J. Cohen, et al. · Neurology · 33
Home intravenous antibiotic treatment for febrile episodes in immune-compromised pediatric patients
1998 · E. Shemesh, I. Yaniv, et al. · Medical and Pediatric Oncology · 33
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
2020 · P. Berlanga, C. Pasqualini, et al. · European Journal of Cancer · 31
PDF
Excellent Prognosis in a Subset of Patients with Ewing Sarcoma Identified at Diagnosis by CD56 Using Flow Cytometry
2011 · Shifra Ash, Drorit Luria, et al. · Clinical Cancer Research · 31
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
2019 · Ruth Lydia Ladenstein, Ulrike Poetschger, et al. · Journal of Clinical Oncology · 30
Reduced levels of miR‐34a in neuroblastoma are not caused by mutations in the TP53 binding site
2009 · Galina Feinberg‐Gorenshtein, Smadar Avigad, et al. · Genes Chromosomes and Cancer · 28
Works count: 111
Citation count: 2,193
H-index: 27
I10-index: 62
Year
Topic
Type